Intersect ENT, Inc. (XENT) |
|
28.24 0 (0%)
|
08-19 01:41 |
|
Open: |
28.25 |
Pre. Close: |
28.24 |
|
High:
|
28.25 |
Low:
|
28.23 |
|
Volume:
|
0 |
Market Cap:
|
945(M) |
|
|
|
|
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
28.28 - 28.41 |
28.41 - 28.53 |
|
Low:
|
27.89 - 28.06 |
28.06 - 28.2 |
|
Close:
|
28 - 28.25 |
28.25 - 28.46 |
|
Technical analysis |
as of: 2022-08-18 3:57:12 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 32.99 One year: 38.53 |
| Support: |
Support1: 28.23 Support2: 28.22 |
| Resistance: |
Resistance1: 28.25 Resistance2: 32.99 |
| Pivot: |
28.23 |
| Moving Average: |
MA(5): 28.23 MA(20): 28.23
MA(100): 28.13  MA(250): 27.6 |
| MACD: |
MACD(12,26): 0  Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 50 %D(3): 50 |
| RSI: |
RSI(14): 64.9 |
| 52-week: |
High: 28.25 Low: 26.65 |
| Average Vol(K): |
3-Month: 0 (K) 10-Days: 0 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ XENT ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 57 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Sun, 14 Aug 2022
Top 5 2nd Quarter Trades of First Light Asset Management, LLC - GuruFocus.com
Sat, 13 Aug 2022
Intersect ENT (NASDAQ:XENT) Receives New Coverage from Analysts at StockNews.com - Defense World
Thu, 04 Aug 2022
20724 Shares in Intersect ENT, Inc. (NASDAQ:XENT) Purchased by SG Americas Securities LLC - Defense World
Sat, 16 Jul 2022
Reviewing Intersect ENT (NASDAQ:XENT) & Pulmonx (NASDAQ:LUNG) - Defense World
Fri, 13 May 2022
Medtronic completes Intersect ENT acquisition - Mass Device
Fri, 22 Apr 2022
Medtronic's planned purchase of Intersect ENT said expected to close in May (NASDAQ:XENT) - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Medical Devices |
| Shares Out. |
33 (M) |
| Shares Float |
28 (M) |
|
% Held by Insiders
|
1.5 (%) |
|
% Held by Institutions
|
93.5 (%) |
|
Shares Short
|
3,220 (K) |
|
Shares Short P.Month
|
2,030 (K) |
Stock Financials |
|
EPS
|
-2.69 |
|
EPS Est Next Qtl
|
-0.11 |
|
EPS Est This Year
|
-0.62 |
|
EPS Est Next Year
|
-0.39 |
|
Book Value (p.s.)
|
0.49 |
|
Profit Margin (%)
|
-149.6 |
|
Operating Margin (%)
|
-65.3 |
|
Return on Assets (ttm)
|
-23.3 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
8.6 |
|
Gross Profit (p.s.)
|
2.29 |
|
Sales Per Share
|
3.19 |
|
EBITDA (p.s.)
|
-1.94 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-59 (M) |
|
Levered Free Cash Flow
|
-31 (M) |
Stock Valuations |
|
PE Ratio
|
-10.54 |
|
PEG Ratio
|
-2.3 |
|
Price to Book value
|
57.63 |
|
Price to Sales
|
8.85 |
|
Price to Cash Flow
|
-15.89 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
